Obinutuzumab Alternatives Compared
| Obinutuzumab | Imbruvica (ibrutinib) | Venclexta (venetoclax) |
|
|---|
| Obinutuzumab | Imbruvica (ibrutinib) | Venclexta (venetoclax) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Chronic Lymphocytic Leukemia, Follicular Lymphoma. Obinutuzumab may also be used for purposes not listed in this medication guide. |
Prescription only
Imbruvica is an oral tablet that may be taken once daily to treat certain types of cancers in adults or to treat chronic Graft Versus Host disease in adults and children older than 1 year. It works... View more |
Prescription only
Venclexta is a BCL-2 inhibitor that may be used to treat chronic lymphocytic leukemia (CLL), small cell lymphoma (SCL), or acute myeloid leukemia. It is an oral tablet that is administered once... View more |
Related suggestions Chronic Lymphocytic Leukemia
|
|||||||||||||||
| More about Obinutuzumab | More about Imbruvica (ibrutinib) | More about Venclexta (venetoclax) | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Obinutuzumab has an average rating of 9.8 out of 10 from a total of 5 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Imbruvica has an average rating of 6.4 out of 10 from a total of 63 ratings on Drugs.com. 58% of reviewers reported a positive effect, while 32% reported a negative effect. |
Venclexta has an average rating of 8.7 out of 10 from a total of 10 ratings on Drugs.com. 80% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Side Effects | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
N/A |
||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Imbruvica prices |
View all Venclexta prices |
||||||||||||||||
| Dosage Forms Available | ||||||||||||||||||
|
N/A |
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Gazyva |
N/A |
N/A |
||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||
|
681.6 hours |
6 hours |
26 hours |
||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 172 drugs are known to interact with Obinutuzumab:
|
A total of 483 drugs are known to interact with Imbruvica:
|
A total of 438 drugs are known to interact with Venclexta:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
|
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
N/A |
November 13, 2013 |
April 11, 2016 |
||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.